Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Lilly licenses Lycia’s LYTAC protein degrader platform
by Megha Satyanarayana
August 30, 2021
| A version of this story appeared in
Volume 99, Issue 31
Eli Lilly and Company will license Lycia Therapeutics’ lysosome-based protein degrader technology for $35 million and up to $1.6 billion in future payments. With its lysosomal targeting chimera (LYTAC) technology, Lycia aims to create small molecules and antibodies targeting difficult-to-drug proteins, including cell surface receptors and secreted proteins. The technology was developed by chemical biologist Carolyn Bertozzi at Stanford University. She has resigned her board seat at Lilly.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X